NL-OMON42165已完成4 期
A phase 4, monocenter, randomized, open label, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the glucagon-like peptide-1 receptor agonist lixisenatide versus insulin glulisine on renal physiology and biomarkers in insulin glargine-treated patients with type 2 diabetes mellitus - ELIXIRS: Effect of LIXIsenatide on the Renal System
Diabetes Centrum / Interne Geneeskunde0 个研究点目标入组 82 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Main study:
- •Type 2 diabetes mellitus
- •Both genders (females must be post-menopausal; no menses >1 year)
- •Age: 35 - 75 years
- •BMI: >25 kg/m2
- •HbA1c: 6.5 - 10% DCCT (48 - 86 mmol/mol International Federation of Clinical Chemistry)
- •Stable treatment with basal insulin glargine (dose ±20%) and metformin or basal insulin glargine (dose ±20%) alone for at least 3 months
- •Fasting plasma glucose (FPG) <10 mmol/L or the use of >50 units of basal insulin glargine
- •Hypertension should be under control, i.e. <140/90 mmHg, and treated with a RAAS-interfering agent (ACE-I or ARB) for at least 3 months.
- •Albuminuria should be treated with a RAAS-interfering agent (ACE-I or ARB) for at least 3 months.
- •Written informed consent;Substudy:
- •Male and female patients with type 1 diabetes (as a homogenous model of DKD) with:
- •Normal eGFR (MDRD >=60 mL/min/1.73m2) and normoalbuminuria (spot urine: ACR 3-30 mg/mmol)
- •Normal eGFR (MDRD >=60 mL/min/1.73m2) and microalbuminuria (spot urine: ACR 3-30 mg/mmol)
- •Normal eGFR (MDRD >=60 mL/min/1.73m2) and macroalbuminuria (spot urine: ACR >30 mg/mmol)
- •Reduced eGFR (MDRD <45 mL/min/1.73m2) and macroalbuminuria (spot urine: ACR >30 mg/mmol) ;We will include 6 type 1 diabetes patients per group. ;For control groups, we will collect spot-urine sample from:
- •Healthy age- and BMI-matched subjects (negative control; normal eGFR and normoalbuminuria)
- •Patients with biopsy-proven DKD (positive control; any type of diabetes, eGFR or albuminuria)
- •Patients with IgA nephropathy and albuminuria (to assess specificity for DKD)
- •We will include 6 subjects/patients per group.
排除标准
- •Main study:
- •Current/chronic use of the following medication: TZD, SU derivative, GLP-1RA, DPP-4I, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics, will only be excluded when these drugs cannot be stopped for the duration of the study.
- •Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, head-ache or back ache). However, no such drugs can be taken within a time-frame of 2 weeks prior to renal-testing
- •Hypoglycemia unawareness based on investigator judgment
- •History of severe hypoglycemia that required emergency hospital treatment within 3 months prior to screening
- •Estimated GFR <60 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation)
- •Current urinary tract infection and active nephritis
- •Recent (<6 months) history of cardiovascular disease, including:
- •oAcute coronary syndrome
- •oChronic heart failure (New York Heart Association grade II-IV)
- •oStroke or transient ischemic neurologic disorder
- •Complaints compatible with or established gastroparesis, neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan)
- •Active liver disease or a 3-fold elevation of liver enzymes (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)) at screening
- •History of or actual pancreatic disease
- •History of or actual malignancy (except basal cell carcinoma)
- •History of or actual severe mental disease
- •Substance abuse (alcohol: defined as >4 units/day)
- •Allergy to any of the agents used in the study (i.e. GLP-1RA, inulin, metacresol (component lixisenatide and insulin glulisine), PAH, latex (component of PAH vial stopper))
- •Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study
- •Inability to understand the study protocol or give informed consent;Sub study:
- •See inclusioncriteria
研究者
相似试验
进行中（未招募）
1 期
The renal effects of lixisenatide (a novel, gut-hormone based diabetes drug) and insulin glulisine (a common, wideley diabetes drug)Type 2 Diabetes MellitusEUCTR2014-002178-35-NLVU University Medical Center40
招募中
1 期
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic TherapyMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785Plaque PsoriasisCTIS2023-509738-20-00AbbVie Deutschland GmbH & Co. KG336
招募中
4 期
A study to evaluate the safety and effectiveness of Saroglitazar 4 mg in patients with NAFLD with comorbiditiesCTRI/2023/05/053326Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
招募中
4 期
To Evaluate The Safety and Efficacy of Pertuzumab and Trastuzumab (Phesgo)in Breast Cancer PatientsCTRI/2023/02/050070Roche Products India Pvt Ltd
进行中（未招募）
不适用
A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infected subjects with raised cholesterol - Rocket IIHIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2008-002043-16-ITGilead Sciences Europe Ltd160